Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2000

View Archived Issues

NIH offers type I TNF receptor regulator for licensing

Wnt protein signaling found to control adipogenesis

Researchers discover protein required for protein translocation in bacteria

Licensing opportunity from NIH: gene amplification in cancer

NIH licensing opportunity: methods to inhibit cell motility

Atrix to use drug delivery technology to develop products for Pfizer

NIH licensing opportunity: system for functional identification of p53 mutations

NIH licensing opportunity: novel methods for MRA use in vessel delineation

CPMP recommends marketing approval for Serono's new treatment of female infertility

Viragen to file IND for Omniferon, enroll additional patients in HCV trial

Tularik initiates phase I study of anti-cytomegalovirus compound

Triangle Pharmaceuticals to proceed with Coactinon development

Novavax begins clinical trials of testosterone HRT

EpiCept to begin clinical development of cancer pain therapy

Zonagen receives SBIR grant to study SPRMs for endometriosis

GPC Biotech and Bayer establish antibacterial collaboration agreement

Swiss agency issues preapproval letter for Forcaltonin

Novartis on schedule for 2001 launch of Zelmac

Novel cell adhesion antagonists described

New compounds interacting with 5-HT4 receptor useful for gastrointestinal disorders

New series of tricyclic vasopressin agonists under study at AHP

New selective 5-HT3 antagonists useful as antiemetics

Novel AMPA antagonists under study at Kyorin

Novel antifungal agents under development at SS Pharmaceutical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...